KR101793531B1 - A composition and functional food comprising an combination extract of Atractylodes macrocephala KOIDZ, Morus alba L., Lycium chinensis, Euphoria lingan STEUD, Achyranthus japonica NAKAI, Eucommia ulmoides OLIV and Asparagus cochinchinensis MERR for preventing or treating postmenopause syndrome - Google Patents
A composition and functional food comprising an combination extract of Atractylodes macrocephala KOIDZ, Morus alba L., Lycium chinensis, Euphoria lingan STEUD, Achyranthus japonica NAKAI, Eucommia ulmoides OLIV and Asparagus cochinchinensis MERR for preventing or treating postmenopause syndrome Download PDFInfo
- Publication number
- KR101793531B1 KR101793531B1 KR1020170036775A KR20170036775A KR101793531B1 KR 101793531 B1 KR101793531 B1 KR 101793531B1 KR 1020170036775 A KR1020170036775 A KR 1020170036775A KR 20170036775 A KR20170036775 A KR 20170036775A KR 101793531 B1 KR101793531 B1 KR 101793531B1
- Authority
- KR
- South Korea
- Prior art keywords
- combination
- red pepper
- weight
- herbal medicine
- ginger
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 54
- 240000000249 Morus alba Species 0.000 title claims abstract description 14
- 235000008708 Morus alba Nutrition 0.000 title claims abstract description 14
- 235000013376 functional food Nutrition 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 title abstract description 46
- 244000248539 Asparagus cochinchinensis Species 0.000 title abstract description 3
- 235000009292 Asparagus cochinchinensis Nutrition 0.000 title abstract description 3
- 241000092665 Atractylodes macrocephala Species 0.000 title abstract description 3
- 244000241872 Lycium chinense Species 0.000 title abstract description 3
- 244000237330 gutta percha tree Species 0.000 title abstract description 3
- 241001539473 Euphoria Species 0.000 title description 2
- 206010015535 Euphoric mood Diseases 0.000 title description 2
- 244000184734 Pyrus japonica Species 0.000 title description 2
- 208000011580 syndromic disease Diseases 0.000 title description 2
- 206010027304 Menopausal symptoms Diseases 0.000 claims abstract description 42
- 230000036541 health Effects 0.000 claims abstract description 14
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 11
- 241000411851 herbal medicine Species 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 21
- 235000008397 ginger Nutrition 0.000 claims description 21
- 241000234314 Zingiber Species 0.000 claims description 19
- 240000004160 Capsicum annuum Species 0.000 claims description 15
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims description 15
- 235000007862 Capsicum baccatum Nutrition 0.000 claims description 15
- 239000001728 capsicum frutescens Substances 0.000 claims description 15
- 241001247821 Ziziphus Species 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 13
- 230000006872 improvement Effects 0.000 claims description 10
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 8
- 240000006891 Artemisia vulgaris Species 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 206010060800 Hot flush Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 230000009245 menopause Effects 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 7
- 208000006820 Arthralgia Diseases 0.000 claims description 6
- 244000068485 Convallaria majalis Species 0.000 claims description 6
- 235000009046 Convallaria majalis Nutrition 0.000 claims description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 206010022437 insomnia Diseases 0.000 claims description 6
- 206010019233 Headaches Diseases 0.000 claims description 5
- 208000000112 Myalgia Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 231100000869 headache Toxicity 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 208000002173 dizziness Diseases 0.000 claims description 4
- 208000013465 muscle pain Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000033830 Hot Flashes Diseases 0.000 claims description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 8
- 229910052748 manganese Inorganic materials 0.000 claims 8
- 239000011572 manganese Substances 0.000 claims 8
- 240000002853 Nelumbo nucifera Species 0.000 claims 4
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims 4
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims 4
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims 3
- 239000003163 gonadal steroid hormone Substances 0.000 claims 3
- 241000238633 Odonata Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 12
- 238000002474 experimental method Methods 0.000 abstract description 12
- 241000699670 Mus sp. Species 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000000386 athletic effect Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000037147 athletic performance Effects 0.000 abstract description 2
- 238000005259 measurement Methods 0.000 abstract description 2
- 240000005748 Achyranthes aspera Species 0.000 abstract 1
- 235000005517 Achyranthes aspera Nutrition 0.000 abstract 1
- 240000001008 Dimocarpus longan Species 0.000 abstract 1
- 235000000525 Dimocarpus longan Nutrition 0.000 abstract 1
- 235000000235 Euphoria longan Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 18
- 239000012676 herbal extract Substances 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 235000013305 food Nutrition 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000009806 oophorectomy Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 238000001794 hormone therapy Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000193388 Bacillus thuringiensis Species 0.000 description 3
- 240000003023 Cosmos bipinnatus Species 0.000 description 3
- 235000005956 Cosmos caudatus Nutrition 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000234280 Liliaceae Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 229930003451 Vitamin B1 Natural products 0.000 description 3
- 229930003471 Vitamin B2 Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229940097012 bacillus thuringiensis Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- -1 mucus Chemical compound 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- 235000010374 vitamin B1 Nutrition 0.000 description 3
- 239000011691 vitamin B1 Substances 0.000 description 3
- 235000019164 vitamin B2 Nutrition 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- GMBQZIIUCVWOCD-UQHLGXRBSA-N (25R)-5beta-spirostan-3beta-ol Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 GMBQZIIUCVWOCD-UQHLGXRBSA-N 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 206010016825 Flushing Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000255893 Pyralidae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 241000234299 Zingiberaceae Species 0.000 description 2
- 244000126002 Ziziphus vulgaris Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 229940077731 carbohydrate nutrients Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 229960004232 linoleic acid Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000011147 magnesium chloride Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000012358 sourcing Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001457 vasomotor Effects 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- JQNVCUBPURTQPQ-UHFFFAOYSA-N (25R)-Inokosterone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(CO)C)CCC33O)C)C3=CC(=O)C21 JQNVCUBPURTQPQ-UHFFFAOYSA-N 0.000 description 1
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 239000001169 1-methyl-4-propan-2-ylcyclohexa-1,4-diene Substances 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000219317 Amaranthaceae Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100322915 Caenorhabditis elegans akt-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 102100029951 Estrogen receptor beta Human genes 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 239000000899 Gutta-Percha Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- JQNVCUBPURTQPQ-FTWMDKANSA-N Inokosterone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@@](O)([C@@H](O)CC[C@H](CO)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 JQNVCUBPURTQPQ-FTWMDKANSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 240000000342 Palaquium gutta Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000010161 Student-Newman-Keuls test Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000009661 fatigue test Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 229920000588 gutta-percha Polymers 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- JQNVCUBPURTQPQ-XDWLXSIGSA-N inokosterone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(CO)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 JQNVCUBPURTQPQ-XDWLXSIGSA-N 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 150000007875 phellandrene derivatives Chemical class 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000000837 restrainer Substances 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229950002323 smilagenin Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RMNIZOOYFMNEJJ-UHFFFAOYSA-K tripotassium;phosphate;hydrate Chemical compound O.[K+].[K+].[K+].[O-]P([O-])([O-])=O RMNIZOOYFMNEJJ-UHFFFAOYSA-K 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 235000020334 white tea Nutrition 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Description
본 발명의 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동의 조합생약 추출물을 유효성분으로 함유하는 조성물은 갱년기 유발 마우스를 이용하여 지구적 운동능력과 꼬리피부온도를 측정한 바, 지구적 운동시간이 증가하고, 꼬리피부온도 상승이 억제됨을 확인하였다. 그러므로 본 발명의 조성물은 폐경기 전후 혹은 질환에 의한 체내 여성호르몬 수치의 변화, 여성호르몬 작용의 변화와 관련된 갱년기증후군의 예방 및 개선에 유용하다. The composition containing the herbal extracts of the present invention as an active ingredient in combination with the herbal extracts of the present invention has the ability to measure the global athletic ability and the skin temperature of the tail using the menopausal mice, Increased exercise time, and increased skin temperature. Therefore, the composition of the present invention is useful for prevention and improvement of menopausal syndrome related to change in female hormone levels and female hormone action before and after menopause or disease.
[문헌 1] 한국 등록특허 10-1400913호[Patent Document 1] Korea Patent No. 10-1400913
[문헌 2] 한국등록특허 10-0419121호[Patent Document 2] Korean Patent No. 10-0419121
[문헌 3] 정보섭 외 1인, 도해향약대사전, 영림사, pp545-548, 1998년[Literature 3] Ipseub et al. 1, Daeheejaejang, Daeheejang, Yeonglim, pp545-548, 1998
[문헌 4] 정보섭 외 1인, 도해향약대사전, 영림사, pp826-828, 1998년[Literature 4] Ipseub et al. 1, Daehae Encyclopedia, Young Lim, pp. 826-828, 1998
[문헌 5] 정보섭 외 1인, 도해향약대사전, 영림사, pp164-165, 1998년[Literature 5] I, I, and others 1
[문헌 6] Paech K, Webb P, Kuiper G, Differential ligand activation of estrogen receptors ER-alpha and ER-beta at AP1 site. Science, 1997, 277; 1508-1510[Patent Literature 6] Paech K, Webb P, Kuiper G, Differential ligand activation of estrogen receptors ER-alpha and ER-beta at AP1 site. Science , 1997,277 ; 1508-1510
[문헌 7] Na-Ra Han, Na-Rae Kim, Hyung-Min Kim Hyun-Ja Jeong, Cysteine prevents Menopausal syndromes in ovariectomized mouse, Reproductive Sci, 2016, 23;670[7] Na-Ra Han, Na-Rae Kim, Hyung-Min Kim Hyun-Ja Jeong, Cysteine prevent menopausal syndromes in ovariectomized mouse, Reproductive Sci , 2016, 23 , 670
[문헌 8] Minghua Li, Chunmei Li, Wade S. Parkhouse, Age-related differences in the des IGF-I-mediated activation of Akt-1 and p70 S6K in mouse skeletal muscle, Mechanisms of Ageing and Development, 2003, 124:771[Document 8] Minghua Li, Chunmei Li, Wade S. Parkhouse, Age-related differences in the des IGF-I-mediated activation of Akt-1 and p70 S6K in mouse skeletal muscle, Mechanisms of Ageing and Development, 2003, 124: 771
본 발명은 백출, 상심자, 구기자, 용안육, 우슬, 두충, 천문동, 생강 및 대추의 조합생약 추출물을 유효성분으로 함유하는, 갱년기증후군을 치료 및 예방하는 조성물에 관한 것이다.The present invention relates to a composition for treating and preventing menopausal syndrome, which comprises, as an active ingredient, a herbal medicine extract of a combination of Pyrrhiza edulis, Liliaceae, Pyralidae, Pyralidae, Liliaceae,
폐경은 모든 여성에서 나타나는 필연적 현상이기는 하나, 그로 인한 여성호르몬의 결핍은 장기간에 걸쳐 신체적, 정신적 질환을 유발하는 중요한 인자로 작용하게 된다. 소위“폐경기 증후군(postmenopausal syndrome)”은 다양한 증상과 질환을 포함하는데, 발현 시기에 따라 초기의 급성 증상, 중기 증상 및 말기의 장기적 후유증으로 나누어 볼 수 있다. 갱년기 초기의 증상으로는 열성 홍조와 야간발한 등 혈관운동성 증상과 정신적, 심리적 증상이 있으며, 폐경 기간이 경과함에 따라 소실되는 제한적인 특성을 보인다. 중기 증상으로는 비뇨생식계 위축 증상과 신체 각 부위의 결체조직으로부터 교원질이 감소됨으로써 나타나는 증상 등을 들 수 있다. 이 중기 증상은 제한적 특성을 보이는 급성 초기 증상과는 달리 폐경기간이 경과함에 따라 더욱 악화하는 과정을 취한다.Menopause is an inevitable phenomenon in all women, but the resulting deficiency of female hormones is an important factor that causes physical and mental diseases over a long period of time. The so-called " postmenopausal syndrome " includes various symptoms and diseases, which can be classified into early acute symptoms, mid-term symptoms, and long-term sequelae of the terminal period. The early symptoms of menopause include vasomotor symptoms such as hot flushes and night sweats, and mental and psychological symptoms, which show limited characteristics that disappear with the passage of menopause. Mid-term symptoms include symptoms of atrophy of the urogenital system and symptoms caused by collagen loss from the connective tissue of each part of the body. This mid-term symptom, as opposed to acute initial symptoms with limited characteristics, is exacerbated as the menopausal period elapses.
폐경기간이 매우 경과함에 따라 나타나는 말기의 장기적 후유증으로는 골다공증, 심혈관질환과 뇌혈관질환이 대표적 질환이며 노인성 치매 등이 이 범주에 속한다. (박형무. 갱년기 증상과 여성호르몬 치료. 대한의사협회지 49권 1호 11-29)The long-term after effects of the late menopausal period, such as osteoporosis, cardiovascular disease and cerebrovascular disease, are the major diseases and senile dementia. (Hwang, Hyung-moo) Menopausal Symptoms and Female Hormone Therapy Korean Medical Journal, Vol. 49, No. 1, 11-29,
1980년대 이후 국내에서 수행된 폐경 관련 증상을 파악한 연구결과에 의하면 우리나라 폐경기 여성의 폐경증상 경험률은 57%에서 90%에 이르며 경험하는 증상의 범위는 신경예민, 근골격계 증상, 피로 및 전신쇠약, 두통의 빈도와 강도가 높게 나타났다. 폐경 증상 중 안면홍조, 발한 등의 혈관운동증상은 1980년대 보고율보다 1990년대 후반 연구에서 증상 호소율이 증가되는 것으로 보고되었다. 2000년대 연구에서도 자연폐경을 경험한 여성의 89%가 폐경 증상 중 적어도 하나를 경험하며, 안면홍조가 61%로 가장 흔한 것으로 보고되었다. (폐경기 증상에 대한 행동양식과 여성건강 관련 실태조사. 과제번호 2012-E63013-00. 질병관리본부)According to the results of a study on postmenopausal symptoms performed in Korea since the 1980s, the prevalence rate of menopausal symptoms in postmenopausal women in Korea has ranged from 57% to 90%. The range of symptoms experienced is neurosis, musculoskeletal symptoms, fatigue and general weakness, Frequency and intensity. In menopausal symptoms, facial flushing and sweating were reported to be more symptomatic in the late 1990s than in the 1980s. In the 2000s, 89% of women who experienced natural menopause experienced at least one of menopausal symptoms, and facial flushing was reported to be the most common (61%). (Behavioral Patterns of Menopausal Symptoms and Survey on the Actual Conditions of Women's Health) No. 2012-E63013-00.
이와 같은 여성 호르몬 조절 관련 질환 또는 증상을 치료하기 위해 대표적으로 호르몬 요법이 쓰이고 있다. 그러나 호르몬 요법은 유방암, 뇌졸중, 심장마비, 정맥 혈전증, 심혈관계 질환 등의 부작용을 일으킬 수 있는 것으로 나타났다. (한국 등록특허 10-1400913호)Hormone therapy is typically used to treat such diseases or conditions related to female hormone regulation. However, hormone therapy has been shown to cause side effects such as breast cancer, stroke, heart attack, venous thrombosis, and cardiovascular disease. (Korean Patent No. 10-1400913)
이러한 호르몬 요법에 의한 문제점을 극복하기 위하여 천연 생약을 주성분으로 하는 여성 갱년기 증상의 개선제의 개발이 시도되고 있다.In order to overcome the problems caused by the hormone therapy, development of an agent for improving female menopausal symptoms based on natural herbal medicine has been attempted.
백출은 국화과 (Compositae)에 속하는 다년생 초본인 큰꽃삽주 (Atractylodes macrocephala KOIDZ) 및 동속 근연식물의 근경을 칭하는 것으로 정유, 아트락틸론(Atractylone), 아트락티롤(Atractylol) 등의 물질을 함유하고 있으며, 관절염, 각기증, 소변불리 등의 치료에 사용해온 것으로 알려져 있다 (정보섭외, 도해향약대사전, 영림사, pp1026, 1998). Atopy is a perennial herbaceous plant belonging to the family Asteraceae (Compositae), which refers to the root of atractylodes macrocephala KOIDZ and related plants. It contains essential oils, Atractylone and Atractylol. , Arthritis, each donation, urine discomfort, etc. (Information and communication, Daehae Encyclopedia, Yeonglim Corp, pp1026, 1998).
상심자는 뽕나무과 (Moraceae)에 속하는 활엽교목인 뽕나무(Morus alba L.)의 및 동속 근연식물의 종자를 칭하는 것으로 당분, 탄닌산(tannic acid), 리놀산(linoloic acid), 스테아린산 (stearinic acid), 등의 물질을 함유하고 있으며, 소갈증, 관절불리 등의 치료에 사용해온 것으로 알려져 있다 (정보섭외, 도해향약대사전, 영림사, pp545-548, 1998). It is known that Morus alba L. is a seed of Morus alba L. and a relative plant belonging to the Moraceae family. It contains sugar, tannic acid, linolic acid, stearinic acid, It is known to have been used for the treatment of painful joints, joint disadvantages, and the like.
구기자는 가지과 (Solanaceae)에 속하는 덩굴성 관목인 구기자나무 (Lycium chinensis), 영하구기자(Lycium barbarum L.)의 성숙한 과실을 칭하는 것으로 카로텐(carotene), 니코틴산(nicotinc acid), 등의 물질을 함유하고 있으며, 혈당 및 콜리스테롤 강하작용, 혈압저하작용 등을 갖는 것으로 알려져 있다 (정보섭외, 도해향약대사전, 영림사, pp826-828, 1998). Gugija refers to mature fruit of Lycium chinensis, Lycium barbarum L., a vine shrub belonging to Solanaceae, and contains substances such as carotene, nicotinic acid and the like , And has been known to have hypoglycemic and cholesterol lowering effects, blood pressure lowering effects, and the like (Information Sourcing, Illustrated Diary, and Young Lim, pp. 826-828, 1998).
용안육은 무환자나무과 (Sapinaceae)에 속하는 상록교목인 용안 (Euphoria lingan STEUD)의 가종피(假種皮)를 칭하는 것으로 포도당, 서당, 주석산 등의 물질을 함유하고 있으며, 불면, 건망증 등의 치료에 사용해온 것으로 알려져 있다 (정보섭외, 도해향약대사전, 영림사, pp371-373, 1998). Ryeonggak refers to the epidermis of Euphoria lingan STEUD, an evergreen tree belonging to the Sapinaceae family. It contains substances such as glucose, seoddang and tartaric acid, and has been used for the treatment of insomnia and forgetfulness. (Information Sourcing, Dictionary of Contemplation of Diagrams, Yeonglim Publishing House, pp 371-373, 1998).
우슬은 비름과 (Amaranthaceae)에 속하는 다년생 초본인 쇠무릎 (Achyranthus japonica NAKAI) 혹은 우슬 (Acyranthes bidentata Blume)의 근을 칭하는 것으로 트리테르페노이드 사포닌 (triterpeoid saponin), 엑디스테론(ecdysterone), 이노코스테론(inokosterone) 등의 물질을 함유하고 있으며, 자궁수축작용, 혈압강하작용, 진통작용 등의 치료에 사용해온 것으로 알려져 있다 (정보섭외, 도해향약대사전, 영림사, pp340-342, 1998). It is called the root of Achyranthus japonica NAKAI or Acyranthes bidentata Blume belonging to the Amaranthaceae. It is composed of triterpeoid saponin, ecdysterone, (inokosterone), and has been used in the treatment of uterine contraction, hypotension, and analgesia.
두충은 두충과 (Eucommiaceae)에 속하는 활엽교목인 두충나무 (Eucommia ulmoides OLIV)의 수피를 칭하는 것으로 구타-페르카(gutta-percha), 알칼로이드(alkaloid), 펙틴(pectin), 케토스(ketose), 리놀산 (linoleic aicd) 등의 물질을 함유하고 있으며, 혈압강하작용, 이뇨작용 등이 알려져 있다 (정보섭외, 도해향약대사전, 영림사, pp605-606, 1998). It refers to the bark of Eucommia ulmoides OLIV, a benthic tree belonging to the Eucommiaceae, and is composed of gutta-percha, alkaloid, pectin, ketose, And linoleic acid (linoleic aicd), and blood pressure lowering action, diuretic action, etc. are known (Information Information, Illustrated Dictionary of Dietary Encouragement, Younglim Corp, pp605-606, 1998).
천문동은 백합과 (Liliaceae)에 속하는 다년성 덩굴성 초본인 천문동 (Asparagus cochinchinensis MERR)의 괴경을 칭하는 것으로 아스파라긴(asparagine), 점액질, 시토스테롤 (sitosterol), 스밀라게닌(smilagenin) 등의 물질을 함유하고 있으며, 항균작용, 살충작용, 항궤양작용 등이 알려져 있다 (정보섭외, 도해향약대사전, 영림사, pp164-165, 1998). Chunmunmdong refers to a tuber of a multi-annual vine herb, Asparagus cochinchinensis MERR, belonging to the Liliaceae and contains substances such as asparagine, mucus, sitosterol and smilagenin , Antimicrobial action, insecticidal action, and anti-ulcer action are known.
생강은 생강과 (Zingiberaceae)에 속하는 다년성 초본인 생강 (Zingiber officinale ROSC)의 근경을 칭하는 것으로 징기베롤(zingiberol), 징기베론(zingiberone), 펠란드렌(phellandrene), 진저롤(gingerol), 쇼가올(shogaol), 등의 물질을 함유하고 있으며, 항균 및 항기생충 작용 등이 알려져 있다 (정보섭외, 도해향약대사전, 영림사, pp260-262, 1998). Ginger refers to the root of a ginger (Zingiber officinale ROSC), a multi-annual herb ginger (Zingiberaceae) belonging to the genus Zingiberaceae, and is a zingiberol, zingiberone, phellandrene, gingerol, (Shogaol), etc., and antimicrobial and antiparasitic activities are known. (Information, Outline, Illustrated Dictionary of Containing Medicine, Young Lim, pp. 260-262, 1998).
대추는 갈매나무과 (Rhamnaceae)에 속하는 활엽교목인 대추나무 (Zizyphus jujuba MILL)의 과실을 칭하는 것으로 단백질, 유기산, 등의 물질을 함유하고 있으며, 근육강화, 간장보호, 체중증가 작용 등이 알려져 있다 (정보섭외, 도해향약대사전, 영림사, pp296-297, 1998). Jujube refers to the fruit of the jujube (Zizyphus jujuba MILL), a broad-leaved tree belonging to the Rhamnaceae family. It contains substances such as protein, organic acid, etc., and it is known to strengthen muscles, protect the liver and increase weight Information and Communication, Daehee Medicinal Dictionary, Yeonglim Publishing House, pp296-297, 1998).
그러나, 상기 문헌의 어디에도 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동의 조합생약을 유효성분으로 함유하는 갱년기증후군 혹은 유사증상에 대한 예방, 억제, 개선, 혹은 치료에 대하여 개시되거나 교시된 바가 없다. However, none of the above-mentioned documents discloses or suggests prevention, suppression, improvement, or treatment of menopausal syndrome or similar symptoms containing an effective ingredient of a combination herbal medicine comprising extracts of Bacillus thuringiensis, Bacillus thuringiensis, Bacillus thuringiensis, There is no bar.
이에 따라, 본 발명자는 갱년기증후군의 개선에 탁월한 천연물을 찾고자 연구하였고 본 발명의 조합 추출물이 갱년기 동물 실험과 간이 임상실험에서 탁월한 갱년기증후군 개선효과를 나타냄을 확인함으로써 본 발명을 완성하였다. Accordingly, the present inventors have searched for natural substances superior to the improvement of the menopausal syndrome and confirmed that the combination extract of the present invention exhibits an excellent menopausal syndrome improvement effect in a menopausal animal experiment and a simple clinical experiment, thereby completing the present invention.
상기 목적을 해결하기 위해 본 발명은 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동으로 구성된 조합생약 추출물을 유효성분으로 함유하는 갱년기증후군의 치료 및 예방용 약학조성물을 제공한다. In order to solve the above-mentioned problems, the present invention provides a pharmaceutical composition for the treatment and prevention of a menopausal syndrome which comprises as an active ingredient, a combination herbal medicine extract consisting of Baekjoo, Bokseongjae, Gujija,
또한, 본 발명은 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동으로 구성된 조합생약 추출물을 유효성분으로 함유하는 갱년기증후군의 예방 및 개선용 건강기능식품을 제공한다.The present invention also provides a health functional food for preventing and ameliorating a menopausal syndrome which comprises an extract of a combination herbal medicine consisting of a herbal extract, a herbal extract, a gojira, a yanglani,
본원에서 정의되는 조합생약 추출물은 정제수를 포함한 물, C1 내지 C4의 저급알코올 또는 이들의 혼합용매, 바람직하게는 물 또는 물 및 알콜 혼합용매에 가용한 추출물을 포함한다.Combination herbal extracts as defined herein include extracts that are soluble in water, including purified water, C1 to C4 lower alcohols or mixed solvents thereof, preferably water or a mixed solvent of water and alcohol.
본원에서 정의되는 조합생약 추출물은 추가적으로, 생강 및 대추로 구성된 하나 이상의 생약 추출물; 비타민 A, 비타민 E, 비타민 B1, 비타민 B2, 비타민 B6, 비타민 B12, 비타민 C, 비오틴, 니코틴산아미드, 엽산, 및 판토텐산 칼슘으로부터 구성된 군으로부터 선택된 하나 이상의 비타민류; 및/또는 황산 제1철, 산화아연, 탄산마그네슘, 제1인산칼륨, 제2인산칼슘, 구연산 칼륨, 탄산칼슘, 및 염화마그네슘으로부터 구성된 군으로부터 선택된 하나 이상의 무기질을 포함함을 특징으로 한다.Combination herbal extracts as defined herein further comprise one or more herbal extracts consisting of ginger and jujube; One or more vitamins selected from the group consisting of vitamin A, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, biotin, nicotinamide, folic acid, and calcium pantothenate; And / or at least one inorganic substance selected from the group consisting of ferrous sulfate, zinc oxide, magnesium carbonate, potassium monophosphate, calcium diphosphate, potassium citrate, calcium carbonate, and magnesium chloride.
본원에서 정의되는 조합생약 추출물의 바람직한 배합 중량부로는 (a) 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동의 조합인 경우는, 백출 1 내지 10, 상심자 1 내지 10, 구기자 1 내지 10, 용안육 1 내지 10, 우슬 1 내지 10, 두충 1 내지 10, 및 천문동 1 내지 10의 중량부(w/w), 보다 바람직하게는 백출 1 내지 5, 상심자 1 내지 5, 구기자 1 내지 5, 용안육 1 내지 5, 우슬 1 내지 5, 두충 1 내지 5 및 천문동 1 내지 5의 중량부(w/w), 보다 더 바람직하게는 백출 1 내지 3, 상심자 1 내지 3, 구기자 1 내지 3, 용안육 1 내지 3, 우슬 1 내지 3, 두충 1 내지 3 및 천문동 1 내지 3의 중량부(w/w),로 배합된 조합을 포함하며; (b) 백출, 상심자, 구기자, 용안육, 우슬, 두충, 천문동, 생강 및 대추의 조합인 경우는, 백출 1 내지 10, 상심자 1 내지 10, 구기자 1 내지 10, 용안육 1 내지 10, 우슬 1 내지 10, 두충 1 내지 10, 천문동 1 내지 10, 생강 1 내지 10 및 대추 1 내지 10의 중량부(w/w), 보다 바람직하게는 백출 1 내지 5, 상심자 1 내지 5, 구기자 1 내지 5, 용안육 1 내지 5, 우슬 1 내지 5, 두충 1 내지 5, 천문동 1 내지 5, 생강 1 내지 5 및 대추 1 내지 5의 중량부(w/w), 보다 더 바람직하게는 백출 1 내지 3, 상심자 1 내지 3, 구기자 1 내지 3, 용안육 1 내지 3, 우슬 1 내지 3, 두충 1 내지 3, 천문동 1 내지 3, 생강 1 내지 2 및 대추 1 내지 2의 중량부(w/w)로 배합된 조합을 포함함을 특징으로 한다.The preferred combination weight of the crude herbal medicine extracts as defined herein is (1) a combination of a herbal extract, a herbarium, a mackerel, a yogurt, a yogurt, (W / w), more preferably 1 to 5 parts by weight, more preferably 1 to 5 parts by weight, from 1 to 10 parts by weight, from 1 to 10 parts by weight, from 1 to 10 parts by weight, from 1 to 10 parts by weight, from 1 part by weight to 10 parts by weight, (W / w), more preferably 1 to 3 parts by weight, 1 to 5 parts by weight, 1 to 5 parts by weight, 1 to 5 parts by weight, 1 to 5 parts by weight and 1 to 5 parts by weight, (W / w) of Pigment 1 to 3, Wassle 1 to 3, Piglets 1 to 3, and Pigment 1 to 3; (b) In the case of a combination of red pepper, red pepper, red pepper, yongcheng, mulberry, mulberry, astringent gong, ginger and jujube, (W / w), more preferably from 1 to 5, from 1 to 5, from 1 to 5, from 1 to 5, from 1 to 10, from 2 to 10, from 1 to 10 from ginger, from 1 to 10 from ginger, (W / w), more preferably 1 to 3 times, 3 to 5 times, 1 to 5 times, 5 to 10 times, 1 to 5 times, 1 to 5 times, 1 to 5 times, 1 to 5 times, (W / w) blended with 1 to 3 parts by weight of ginger 1 to 3, ginger 1 to 3, puppet gum 1 to 3, worm 1 to 3, gum 1 to 3, gum 1 to 3, ginger 1 to 2 and jujube 1 to 2 And combinations thereof.
본원에서 정의되는 “갱년기 증후군”은 바람직하게는, 폐경기 전후 혹은 질환에 의한 갱년기증후군, 보다 바람직하게는, 성호르몬의 변화와 연관된, 피로, 열성홍조, 혈관운동증상, 우울, 불안, 어지러움, 두통, 관절통, 근육통, 골다공증, 불면, 질건조증 등의 증상이나 징후 중 전부 혹은 일부를 포함함을 특징으로 하는 증후군이다.The term "menopausal syndrome" as defined herein is preferably selected from the group consisting of premenopausal or postmenopausal or menopausal syndromes due to a disease, more preferably, fatigue, hot flashes, vasomotor symptoms, depression, anxiety, dizziness, headache , Arthralgia, myalgia, osteoporosis, insomnia, dryness of vagina, and the like.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 조합생약 추출물은 하기와 같이 수득될 수 있다.Combination herbal extracts of the present invention can be obtained as follows.
본 발명의 조합생약 추출물은 생약 재료인 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동, 필요시, 생강, 대추를 추가한 조합생약을 일정 배합비로 혼합하여, 이 조합 시료를 각각 물로 세척하여 음건 후, 모두 마쇄하여 상기 생약재료 중량의 약 1내지 20배, 바람직하게는 약 2내지 10배에 달하는 부피의 물, C1 내지 C4의 저급알코올 또는 이들의 혼합용매, 바람직하게는 물로, 0 내지 120℃ 온도, 바람직하게는 20 내지 100℃ 온도에서 약 1시간 내지 1일, 바람직하게는 2시간 내지 8시간 동안, 열수 추출, 냉침 추출, 환류 냉각 추출, 초음파 추출 또는 초임계 추출 등의 추출방법, 바람직하게는 열수추출방법으로 추출한 후, 추출액을 냉각 후에 여과하고 여과액을 동결 건조하여 본 발명의 조합생약 추출물을 얻을 수 있다.The combination herbal medicine extract of the present invention is prepared by mixing herbal medicine ingredients such as white tea, liquorice liquor, gugija, yongcheng, liquor, mugwort and mugwort, if necessary, ginger and jujube, at a certain mixing ratio, After shrimp treatment, the mixture is crushed to a volume of about 1 to 20 times, preferably about 2 to 10 times the weight of the herbal material, a C1 to C4 lower alcohol or a mixture thereof, Extraction such as hot water extraction, cold extraction, reflux cooling extraction, ultrasonic extraction or supercritical extraction for about 1 hour to 1 day, preferably for 2 hours to 8 hours at a temperature of 120 to 120 ° C, preferably 20 to 100 ° C Method, preferably a hot water extraction method, the extract is filtered after cooling, and the filtrate is lyophilized to obtain a crude herbal medicine extract of the present invention.
또한 본 발명은 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동으로 구성된 조합생약 추출물을 유효성분으로 함유하는 갱년기증후군의 개선 및 예방용 건강기능식품을 제공한다. In addition, the present invention provides a health functional food for improving and preventing menopausal syndrome, which comprises an extract of a combination herbal medicine consisting of a herbal extract, a herbarium, a lily of the valley, a yanglani, a lily of the valley,
본원에서 정의되는 상기 추출물은 물, 주정, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로부터 선택된 극성용매, 바람직하게는 물 또는 물 및 주정 혼합용매, 보다 바람직하게는 물 또는 20 내지 90% 물 및 주정 혼합용매에 가용한 추출물을 포함한다.The extract as defined herein is a polar solvent selected from water, alcohol, lower alcohols having 1 to 4 carbon atoms or a mixed solvent thereof, preferably water or water and a mixed solvent, more preferably water or 20 to 90% water And an extract that is soluble in the alcohol mixture.
또한 본 발명은 상기 제조방법 및 상기 제조방법으로 제조된 조합생약 추출물을 유효성분으로 함유하는 갱년기증후군의 치료 및 예방을 위한 약학 조성물 및 건강기능식품을 제공한다. The present invention also provides a pharmaceutical composition and a health functional food for the treatment and prevention of menopausal syndrome which comprises the combined herbal medicine extract prepared by the above production method and the above-mentioned manufacturing method as an active ingredient.
상기에서 제조된 조합생약 추출물을 대상으로 in vivo상 갱년기 유발 마우스를 이용하여 지구적 운동능력과 꼬리 피부 온도를 측정하여, 실시예 1~3의 추출물을 투여한 실험군이 음성대조군에 비하여 지구적 운동시간이 증가하고, 꼬리피부온도의 상승이 억제되며, 간이 임상예에서 탁월한 갱년기 증상 개선효과를 나타냄을 확인함으로써, 갱년기증후군 예방 및 치료용 약제, 갱년기 영양보충제 등등 건강보조식품, 건강기능식품을 제조하는 원료로 조합 추출물을 활용할 수 있음을 처음으로 발견한 바, 갱년기증후군에 대한 억제, 예방 및 치료에 유용함을 밝혀냈다.The combined herbal medicine extracts prepared above were measured in terms of global athletic ability and tail skin temperature using an in vivo on-menopausal mouse, and the experimental group administered with the extracts of Examples 1 to 3 was compared with the negative control group It is confirmed that the time is increased, the increase of skin temperature of tail is suppressed, and the effect of improving the menopausal symptom is excellent in a simple clinical example. Thus, a health supplement food and a health functional food such as a drug for prevention and treatment of menopausal syndrome, a menopausal nutritional supplement, Found that the combination extract could be used as a raw material for the prevention and prevention of menopausal syndrome.
따라서, 본 발명은 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동으로 구성된 조합생약 추출물을 유효성분으로 함유하는 갱년기증후군 개선제를 제공한다. Accordingly, the present invention provides an agent for improving menopausal syndrome, which comprises, as an active ingredient, a combination herbal medicine extract consisting of dried or syrupy, dried syrup, gugija,
본 발명의 조성물은, 조성물 총 중량에 대하여 상기 생약 추출물을 0.01 내지 99% 중량으로 포함한다.The composition of the present invention contains the herbal extract in an amount of 0.01 to 99% by weight based on the total weight of the composition.
그러나 상기와 같은 조성은 반드시 이에 한정되는 것은 아니고, 환자의 상태 및 질환의 종류 및 진행 정도에 따라 변할 수 있다.However, the composition is not limited thereto, and may vary depending on the condition of the patient, the type of disease, and the progress of the disease.
본 발명의 추출물을 포함하는 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.Compositions comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.
본 발명에 따른 추출물을 포함하는 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있으며, 이에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 화합물에 적어도 하나 이상의 부형제 적어도 면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세롤젤라틴 등이 사용될 수 있다.The composition containing the extract according to the present invention may be formulated in the form of powders, granules, tablets, capsules, oral preparations such as suspensions, emulsions, syrups and aerosols, external preparations, suppositories and sterilized injection solutions, Examples of carriers, excipients and diluents that can be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient, such as starch, calcium carbonate, sucrose, Or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As a suppository base, witepsol, macrogol, tween 61, cacao paper, laurin, glycerol gelatin and the like can be used.
본 발명의 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 추출물은 1일 0.01 mg/kg 내지 10 g/kg으로, 바람직하게는 1 mg/kg 내지 1 g/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수 있다. 그러므로 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the extract of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the administration route and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the extract is preferably administered at a dose of 0.01 mg / kg to 10 g / kg per day, preferably 1 mg / kg to 1 g / kg per day. The administration may be carried out once a day or divided into several doses. Therefore, the dose is not intended to limit the scope of the present invention in any aspect.
본 발명의 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구 및 직장 또는 정맥등의 방법을 통하여 투여 할 수 있다. The composition of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, including, for example, oral and rectal or intravenous administration.
또한 본 발명은 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동으로 구성된 조합생약 추출물을 유효성분으로 함유하는 갱년기증후군의 개선 및 예방을 위한 건강기능식품을 제공한다. The present invention also provides a health functional food for the improvement and prevention of menopausal syndrome, which comprises an extract of a combination herbal medicine consisting of Baekjoo, Suksikjae, Gugija, Yongsan, Yusu, Jumung,
또한, 본 발명은 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동으로 구성된 조합생약 추출물을 유효성분으로 함유하는 갱년기 영양보충제를 제공한다. Further, the present invention provides a menopausal nutritional supplement containing, as an active ingredient, a combination herbal medicine extract consisting of Baekjong, Sukjima, Gugija, Yonggaku, Wusu, Jugong,
본 발명의 추출물을 포함하는 건강기능식품은 갱년기증후군의 개선 및 예방을 위한 약제, 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 침출차, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다.The health functional food containing the extract of the present invention can be used variously for medicines, foods and drinks for the improvement and prevention of the menopausal syndrome. Examples of the foods to which the extract of the present invention can be added include various foods, beverages, gums, tea, vitamin complex, leach tea, health supplement foods and the like, and they are in the form of powder, granule, tablet, capsule or beverage Can be used.
따라서 또한, 본 발명은 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동의 조합생약 추출물을 유효성분으로 함유하는 피로증후군, 갱년기증후군의 개선 및 예방용 식품첨가제를 제공한다.Accordingly, the present invention also provides a food additive for improving and preventing fatigue syndrome and menopausal syndrome, which comprises as an active ingredient an extract of a combination of a herbal extract, a herbal extract,
본 발명의 추출물을 첨가 가능한 식품형태는 캔디류의 각종 식품류, 음료, 껌, 차, 비타민 복합제 또는 건강보조 식품류인 식품 등을 포함한다.The food forms to which the extract of the present invention can be added include various foods of candy, beverages, gums, tea, a vitamin complex, or foods that are health supplement foods.
본 발명의 건강 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물의 혼합물을 함유하는 것 외에 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등의 디사카라이드, 예를 들어 말토스, 슈크로스 등의 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등)) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ml당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient, such as ordinary beverages, in addition to containing a mixture of the above extract as an essential ingredient in the indicated ratios, have. Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like Sugar, and sugar alcohols such as xylitol, sorbitol, and erythritol. As natural flavors other than those described above, natural flavors (such as tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin)) and synthetic flavors (saccharin, aspartame, etc.) have. The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above-mentioned composition, the composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and intermediates (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
본 발명의 조합생약 추출물을 대상으로 한 in vivo상 마우스를 이용한 지구적 운동능력 평가실험, 꼬리피부온도를 측정한 바, 실험군이 대조군에 비하여 지구적 운동시간이 증가하고, 꼬리피부온도의 상승이 억제되며, 간이 임상예에서 탁월한 갱년기 증상 개선효과를 나타냄을 확인함으로서, 갱년기증상 치료용 약제 혹은 갱년기 영양보충제 등 건강기능식품 혹은 건강보조식품을 제조하는 원료로 조합 추출물을 활용할 수 있음을 처음으로 확인한 바, 갱년기증후군에 대한 억제, 치료, 예방 및 개선에 유용한 약학 조성물 또는 건강기능식품으로 응용할 수 있다. Experimental evaluation of global athletic performance using mice in vivo on herbal extracts of the present invention and measurement of tail skin temperature showed that the experimental group had an increase in global exercise time and a rise in tail skin temperature . It has been confirmed that the combination extract can be used as a raw material for producing a health functional food or a health supplement such as a medicament for the treatment of menopausal symptoms or a menopausal nutritional supplement by confirming that it exhibits an excellent effect for improving menopausal symptoms in a liver clinical sample Bar, and menopausal syndrome, or a health functional food useful for prevention, treatment, prevention and improvement.
이하, 본 발명을 하기 참고예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to the following Reference Examples and Experimental Examples.
단, 하기 참고예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 참고예 및 실험예에 의해 한정되는 것은 아니다.However, the following Reference Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following Reference Examples and Experimental Examples.
실시예 1. 조합예 1 (CB1)의 제조Example 1. Preparation of Preparation Example 1 (CB1)
옴니허브에서 구입한 건조 상태의 생약들을 일정 중량 배합비(백출 1.5, 상심자 1.5, 구기자 1.5, 용안육 2, 우슬 1, 두충 1, 천문동 1, 생강 0.5, 대추 0.5)로 배합한 배합물 중량의 20배 부피의 물을 첨가하고 100℃에서 5시간 동안 추출기(COSMOS660, 경서기계산업)로 환류추출 한 후 100 mesh의 여과망이 부착된 여과조를 이용하여 여과한 후 상등액을 감압 및 농축한 후에 동결 건조하여 조합생약 추출물을 수득하고 기타 성분을 일정 중량 배합비 { 칼슘(굴각칼슘 ㈜KMF) 0.3, 비타민 B1(독일 DSM) 0.003, 및 비타민 B2 0.001 (한국 BASF)}로 배합된 배합물을 추가하여 본 발명의 조합예 (CB1)을 수득하여 하기 실험의 시료로 사용하였다. The dry form of herbal medicines purchased from Omni Herb were mixed at a weight ratio of 20 (1.5 parts by weight, 1.5 parts by weight, 1.5 parts by weight, 1.5 parts by weight, 2 parts by weight, 1 part by weight, 1 part by weight, 1 part by weight, 1 part by weight ginger, 0.5 part by weight) After addition of a volume of water, the mixture was refluxed with an extractor (COSMOS 660, Kyesho Machinery Industries) at 100 ° C for 5 hours, filtered through a filtration tank equipped with a 100 mesh screen, and then the supernatant was vacuum- The herbal extract was obtained and the other components were added in combination with a certain weight ratio {calcium (KMK 0.3), vitamin B1 (German DSM) 0.003, and vitamin B2 0.001 (BASF Korea) (CB1) was obtained and used as a sample in the following experiment.
실시예 2. 조합예 2 (CB2)의 제조Example 2. Preparation of Preparation Example 2 (CB2)
옴니허브에서 구입한 건조 상태의 생약들을 일정 중량 배합비(백출 1.5, 상심자 1.5, 구기자 1.5, 용안육 2, 우슬 2, 두충 2, 천문동 2, 생강 0.5, 대추 0.5)로 배합한 배합물 중량의 20배 부피의 70% 에탄올을 첨가하고 100℃에서 5시간 동안 추출기(COSMOS660, 경서기계산업)로 환류추출 한 후 100 mesh의 여과망이 부착된 여과조를 이용하여 여과한 후 상등액을 감압 및 농축한 후에 동결 건조하여 본 발명의 조합예 (CB2)을 수득하여 하기 실험의 시료로 사용하였다. The dry form of herbal medicines purchased from Omni Herb were mixed at a ratio of 20 times the weight of the blend formulated with a certain weight ratio (1.5, 1.2, 1.5, 2.0, 2, 2, 2, 0.5, 0.5) 70% ethanol of the volume was added and the mixture was refluxed with an extractor (COSMOS 660, Kyorseo Machinery Industry) at 100 ° C for 5 hours. The filtrate was filtered through a filter equipped with a filter mesh of 100 mesh. The supernatant was decompressed and concentrated, (CB2) of the present invention was used as a sample for the following experiment.
실시예 3. 조합예 3 (CB3)의 제조Example 3. Preparation of Preparation Example 3 (CB3)
옴니허브에서 구입한 건조 상태의 생약들을 일정 중량 배합비(백출 1.5, 상심자 1.5, 구기자 1.5, 용안육 2, 우슬 1, 두충 1, 천문동 1)로 배합한 배합물 중량의 20배 부피의 물을 첨가하고 100℃에서 5시간 동안 추출기(COSMOS660, 경서기계산업)로 환류추출 한 후 100 mesh의 여과망이 부착된 여과조를 이용하여 여과한 후 상등액을 감압 및 농축한 후에 동결 건조하여 본 발명의 조합예 (CB3)을 수득하여 하기 실험의 시료로 사용하였다. 20 times as much water as the weight of the blend formulated with the dry ingredients of the omni herb was mixed with a certain weight ratio (1.5: 1.5, 1.2: 1, 1.5: 1, 2: 1, 1: 1, 2: 1, (COSMOS 660, Kyorseo Machinery Industry) at 100 ° C for 5 hours. The filtrate was then filtered through a filter equipped with a 100-mesh screen. The supernatant was then reduced in pressure and concentrated and freeze- ) Was obtained and used as a sample for the following experiment.
실험예Experimental Example 1. 갱년기 동물실험 1. Climacteric Animal Experiment
상기 실시예 시료들의 갱년기증후군 개선 효능을 확인하기 위하여, 문헌에 기재된 난소 절제술을 시행한 갱년기 동물 모델에서 하기와 같이 실험을 수행하였다.In order to confirm the effect of improving the menopausal syndrome of the above-mentioned samples, an experiment was carried out as follows in a menopausal animal model in which ovariectomy was performed as described in the literature.
1-1. 1-1. 실험 동물Experimental animal
7주령의 ICR 마우스(28~30g)을 ㈜오리엔트바이오(Seoul, Korea)에서 공급받아 동물 실험실에 약 5일간 적응시켜 사용하였으며, 물과 사료는 자유롭게 섭취하도록 하였고, 온도(23 ± 2℃), 습도(50 ± 10%) 및 명암 주기(12 시간)는 자동으로 조절되도록 하였다. Seven weeks old ICR mouse (28 ~ 30g) was supplied from Orient Bio Korea and used for 5 days in an animal laboratory. Water and feed were freely taken, temperature (23 ± 2 ℃) Humidity (50 ± 10%) and darkness (12 hours) were automatically adjusted.
1-2. 실험 방법1-2. Experimental Method
1-2-1.1-2-1. 마우스 난소 절제수술Mouse ovariectomy
Park 등의 방법(Park 등, J Korean Neurosurg Soc. 2010, 48; p309)에 근거하여 8 주령의 ICR 마우스를 마취시키고 등쪽 부분을 가위로 자른 후 왼쪽과 오른쪽의 난소 아래 부분을 봉합사로 잘 묶은 다음 난소 부분을 절제하고 등 부분을 봉합사로 마무리하고 소독한 후 항생제를 투여하고 히팅 패드(heating pad)에서 깨어날 때까지 체온을 유지한 후 갱년기 모델 마우스를 제작하였다. 수술 2주 동안 회복기를 거친 후 실험에 사용하였다.An 8-week-old ICR mouse was anesthetized with the use of Park et al. (J Korean Neurosurg Soc. 2010, 48; p309), and the dorsal area was cut with scissors. The ovary was excised, the back was closed with a suture, disinfected, antibiotics were administered, and the body temperature was maintained until waking on a heating pad, to produce a menopausal model mouse. After two weeks of recovery, they were used for the experiment.
1-2-2. 꼬리 피부 온도 측정1-2-2. Tail skin temperature measurement
난소 절제 수술 2주 후부터 본 발명의 시료들을 한 용량군으로 경구 투여하였다. 대조군(Sham)과 음성대조군(OVX+saline)은 생리 식염수를 경구 투여하였다. 투여 2주 후 마우스의 몸무게를 재고 운동 시작 전 꼬리 피부 온도(Tail Skin Temperature)를 측정하기 위해 마우스를 고정틀(restrainer)에 넣고 5분간 안정화를 시킨 후 꼬리 기저부로부터 1 cm 부분을 1분 간격으로 3회 열화상 카메라(FLIR T600, USA)를 이용하여 꼬리의 온도를 측정(Basal temperature, TB)한 후 트레드밀(Exer-3/6, Columbus instruments, USA)에서 15 m/min 속도로 10분 동안 운동을 한 후 다시 고정틀로 옮겨 1분 간격으로 3회 열화상카메라를 이용하여 꼬리 온도(Forced Exercise Temperature, TE)를 측정하였다(Hideki 등, J Pharmacol Sci, 2005,98:323). 운동 전의 온도는 3회 평균값(TB)을 구하였고, 운동 후 측정한 꼬리 피부 온도는 하기 수학식 1에 따라 Total TST를 계산하였다.Samples of the present invention were orally administered in one dose group after 2 weeks of ovariectomy. The control (Sham) and negative control (OVX + saline) were orally administered with physiological saline. The mouse was weighed 2 weeks after the administration and the mouse was placed in a restrainer for 5 minutes to measure the tail skin temperature before starting the exercise. The 1 cm portion from the base of the tail was measured at intervals of 1 minute The temperature of the tail was measured using a rotary camera (FLIR T600, USA) (Basal temperature, T B ), and the treadmill (Exer-3/6, Columbus instruments, USA) After exercise, the animals were moved back to the fixator and the tail temperature (Forced Exercise Temperature, T E ) was measured using an infrared camera three times at intervals of one minute (Hideki et al., J Pharmacol Sci, 2005,98: 323). The temperature before the exercise was calculated as the average of three times (T B ), and the total skin temperature of the tail skin after exercise was calculated by the following formula (1).
갱년기증후군의 증상 중 하나인 열성홍조(hot flush)를 실험하기 위하여 마우스의 난소를 절제하고 2주 동안 실시예 1~3의 추출물을 경구 투여한 후 열화상 카메라를 이용하여 꼬리 피부 온도를 측정하였다. In order to test hot flush, one of the symptoms of menopausal syndrome, ovariectomy of mice was performed and the extracts of Examples 1 to 3 were orally administered for 2 weeks and then the skin temperature of the tail was measured using a thermal camera .
상기 실험 결과, 표 1에서 보는 바와 같이 음성대조군(OVX+saline)에서 TST의 유의성 있는 증가를 확인한 바 난소 절제 수술은 잘 된 것으로 판단할 수 있었다. 실시예 1~3의 추출물을 각각 투여한 실험군은 모두 음성대조군에 비하여, 열성홍조의 지표인 TST가 현저히 감소함을 확인할 수 있었다. As shown in Table 1, when the TST was significantly increased in the negative control (OVX + saline), it was judged that the ovariectomy was successful. It was confirmed that TST, which is an indicator of hot flushes, was significantly reduced in the experimental groups administered with the extracts of Examples 1 to 3, respectively, as compared with the negative control group.
1-2-3. 1-2-3. 트레드밀을Treadmill 이용한 Used 항피로Anti-fatigue 실험 Experiment
갱년기 유발 마우스를 이용하여 실시예 1~3의 추출물 투여에 의한 갱년기 피로 억제 효과를 트레드밀 운동실험으로 평가하였다. Minghua 등의(Mechanisms of Ageing and Development, 2003, 124:771) 방법을 수정하여 트레드밀의 각도를 10도 올린 후 15 m/min 속도로 주행을 시작하고, 3분 간격으로 5 m/min씩 단계적으로 속도를 올려 최대 30 m/min까지 속도를 올리고, 마우스가 주행 불능이 될 때까지의 시간(최대 주행 시간)을 측정하였다.The effects of the extracts of Examples 1 to 3 on the menopausal fatigue were evaluated by a treadmill exercise test using menopausal mice. Minghua et al. (2003, 124: 771) modified the treadmill angle to 10 degrees and started to travel at a speed of 15 m / min. The speed was increased to a maximum of 30 m / min, and the time (maximum driving time) until the mouse became inoperable was measured.
실시예 1~3의 추출물을 2주간 투여한 후 트레드밀을 이용하여 최대 주행 시간을 측정한 결과, 대조군에서 26.2±1.4분 주행하였고 음성대조군에서는 13.7±1.0분으로 유의성 있는 감소를 보였으며, 본 발명의 시료들은 각각 음성대조군에 비하여 현저하게 증가된 최대 주행 시간을 나타냈다 (표 2). As a result of measuring the maximum running time using a treadmill after administering the extracts of Examples 1 to 3 for 2 weeks, the control group showed a significant decrease of 26.2 ± 1.4 minutes and 13.7 ± 1.0 minutes in the negative control group, Were significantly increased compared to the negative control samples The maximum travel time was shown (Table 2).
1-3. 통계처리1-3. Statistical processing
모든 실험 결과는 ANOVA(one way analysis of variance)를 이용하여 통계 처리하였고, 유의성이 인정될 경우 Student-Newman-Keuls Test를 사용하여 p < 0.05 수준 이하에서 유의성 검정을 실시하였다.Statistical analysis was performed using ANOVA (ANOVA). Statistical significance was tested using the Student-Newman-Keuls test when p <0.05 was considered significant.
결론적으로 본 발명의 시료들은 갱년기 유발 마우스의 꼬리 피부 온도 실험에서 우수한 열성홍조(hot flush) 감소효과를 나타내고 갱년기 항피로 실험에서도 탁월한 최대 주행 시간을 보인 바, 갱년기 열성홍조(hot flush) 및 갱년기 피로를 개선하거나 치료한다고 판단된다. In conclusion The samples of the present invention exhibited excellent hot flush reduction effect in the tail skin temperature test of menopausal mice and showed excellent maximum running time in the menopausal anti-fatigue test, It is considered to improve or cure menopausal hot flushes and menopausal fatigue.
실험예 2. 간이 임상실험Experimental Example 2. Simplified Clinical Experiment
폐경을 전후로 갱년기 증후군 증상을 보이는 평균연령 50세의 여성 50명을 대상으로 무작위로 다섯군으로 나누어 상기 실시예의 캅셀 및 시료가 무첨가된 비교군을 1회 2캅셀, 1일 2회씩, 4주간 복용하고, 갱년기 평가 척도인 Kupperman 지수(표 3)의 평균 수치를 구하여, 그 결과를 표 4에 나타내었다.Fifty women with an average age of 50 years, who had symptoms of menopausal symptoms before and after menopause, were randomly divided into five groups, and the comparison group in which the capsule and the sample of the above example were not added was administered twice, twice a day, twice a day for 4 weeks And the average value of the Kupperman index (Table 3), which is a menopausal evaluation index, was obtained. The results are shown in Table 4.
상기 표 4로부터, 시료가 무첨가된 대조군에는 뚜렷한 변화가 없는 반면에, 본원 발명의 시료 조합들에서는 뚜렷한 호전을 나타내어 본 발명의 시료들은 갱년기증후군 개선 효과가 뛰어남을 확인할 수 있었다. From Table 4 above, it can be seen that the samples of the present invention show a marked improvement, and the samples of the present invention are excellent in the improvement of the menopausal syndrome, while there is no significant change in the control group in which the sample is not added.
하기에 본 발명의 추출물을 포함하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, formulation examples of the composition containing the extract of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically explained.
제제예 1. 산제의 제조Preparation Example 1. Preparation of powder
CB1 ----------------------------------------------- 200 mgCB1 ----------------------------------------------- 200 mg
유당 ---------------------------------------------- 100 mgLactose ---------------------------------------------- 100 mg
탈크 ----------------------------------------------- 10 mgTalc ----------------------------------------------- 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above components are mixed and filled in airtight bags to prepare powders.
제제예 2. 정제의 제조Formulation Example 2. Preparation of tablets
CB2 ----------------------------------------------- 200 mgCB2 ----------------------------------------------- 200 mg
옥수수전분 ---------------------------------------- 100 mgCorn starch ---------------------------------------- 100 mg
유당 ---------------------------------------------- 100 mgLactose ---------------------------------------------- 100 mg
스테아린산 마그네슘 --------------------------------- 2 mgMagnesium stearate --------------------------------- 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
제제예 3. 캅셀제의 제조Formulation Example 3. Preparation of capsules
CB3 ----------------------------------------------- 200 mgCB3 ----------------------------------------------- 200 mg
결정성 셀룰로오스 ----------------------------------- 3 mgCrystalline cellulose - 3 mg
락토오스 ----------------------------------------- 14.8 mgLactose ----------------------------------------- 14.8 mg
마그네슘 스테아레이트 ----------------------------- 0.2 mgMagnesium stearate 0.2 mg < RTI ID = 0.0 >
통상의 캅셀제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캅셀제를 제조한다.The above components are mixed in accordance with a conventional method for producing a capsule, and filled in a gelatin capsule to prepare a capsule.
제제예 4. 주사제의 제조Formulation Example 4. Preparation of injection
CB1 ----------------------------------------------- 200 mgCB1 ----------------------------------------------- 200 mg
만니톨 -------------------------------------------- 180 mgMannitol -------------------------------------------- 180 mg
주사용 멸균 증류수 ------------------------------- 2974 mgSterile sterilized distilled water for injection ------------------------------- 2974 mg
Na2HPO4 ,12H2O ---------------------------------------- 26 mgNa 2 HPO 4 , 12H 2 O ---------------------------------------- 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당 (2 ㎖) 상기의 성분 함량으로 제조한다.(2 ml) per ampoule in accordance with the usual injection method.
제제예 5. 액제의 제조Formulation Example 5. Preparation of a liquid preparation
CB2 ----------------------------------------------- 200 mgCB2 ----------------------------------------------- 200 mg
이성화당 -------------------------------------------- 10 gIsing Party -------------------------------------------- 10 g
만니톨 ----------------------------------------------- 5 gMannitol ----------------------------------------------- 5 g
정제수 ----------------------------------------------- 적량Purified water -----------------------------------------------
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100 ml로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.
제제예 6. 건강 식품(영양보충제)의 제조Preparation Example 6. Preparation of health food (nutritional supplement)
CB3 --------------------------------------------- 1000 mgCB3 --------------------------------------------- 1000 mg
비타민 혼합물 -------------------------------------- 적량Vitamin mixture --------------------------------------
비타민 A 아세테이트 ------------------------------- 70 ㎍Vitamin A Acetate ------------------------------- 70 μg
비타민 E ----------------------------------------- 1.0 ㎎Vitamin E ----------------------------------------- 1.0 mg
비타민 B1 --------------------------------------- 0.13 ㎎Vitamin B1 --------------------------------------- 0.13 mg
비타민 B2 --------------------------------------- 0.15 ㎎Vitamin B2 --------------------------------------- 0.15 mg
비타민 B6 ---------------------------------------- 0.5 ㎎Vitamin B6 ---------------------------------------- 0.5 mg
비타민 B12 --------------------------------------- 0.2 ㎍Vitamin B12 --------------------------------------- 0.2 g
비타민 C ------------------------------------------ 10 ㎎Vitamin C ------------------------------------------ 10 mg
비오틴 -------------------------------------------- 10 ㎍Biotin -------------------------------------------- 10 μg
니코틴산아미드 ----------------------------------- 1.7 ㎎Nicotinic acid amide 1.7 mg
엽산 ---------------------------------------------- 50 ㎍Folic acid ---------------------------------------------- 50 g
판토텐산 칼슘 ------------------------------------ 0.5 ㎎Calcium pantothenate ------------------------------------ 0.5 mg
무기질 혼합물 -------------------------------------- 적량Mineral Mixture --------------------------------------
황산제1철 --------------------------------------- 1.75 ㎎Ferrous sulfate 1.75 mg < RTI ID = 0.0 >
산화아연 ---------------------------------------- 0.82 ㎎Zinc oxide - 0.82 mg
탄산마그네슘 ------------------------------------ 25.3 ㎎Magnesium carbonate ------------------------------------ 25.3 mg
제1인산칼륨 --------------------------------------- 15 ㎎Potassium phosphate monohydrate 15 mg
제2인산칼슘 --------------------------------------- 55 ㎎Secondary calcium phosphate --------------------------------------- 55 mg
구연산칼륨 ---------------------------------------- 90 ㎎Potassium citrate ---------------------------------------- 90 mg
탄산칼슘 ----------------------------------------- 100 ㎎Calcium carbonate ----------------------------------------- 100 mg
염화마그네슘 ------------------------------------ 24.8 ㎎Magnesium chloride ------------------------------------ 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
제제예 7. 건강 음료의 제조Formulation Example 7. Preparation of health drink
CB1 -------------------------------------------- 1000 mgCB1 -------------------------------------------- 1000 mg
구연산 ----------------------------------------- 1000 ㎎Citric acid ----------------------------------------- 1000 mg
올리고당 ----------------------------------------- 100 gOligosaccharides ----------------------------------------- 100 g
타우린 --------------------------------------------- 1 gTaurine --------------------------------------------- 1 g
정제수를 가하여 ---------------------------- 전체 900 ㎖Add purified water - 900 ml total
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 ° C for about 1 hour. The resulting solution was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, It is used in the production of the health beverage composition of the invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the compounding ratio may be arbitrarily varied depending on the regional and national preferences such as the demand level, the demanding country, and the intended use.
Claims (14)
상기 조합생약 추출물의 배합 중량부는 (a) 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동의 조합인 경우는, 백출 1 내지 10, 상심자 1 내지 10, 구기자 1 내지 10, 용안육 1 내지 10, 우슬 1 내지 10, 두충 1 내지 10, 및 천문동 1 내지 10의 중량부(w/w)이며; (b) 백출, 상심자, 구기자, 용안육, 우슬, 두충, 천문동, 생강 및 대추의 조합인 경우는, 백출 1 내지 10, 상심자 1 내지 10, 구기자 1 내지 10, 용안육 1 내지 10, 우슬 1 내지 10, 두충 1 내지 10, 천문동 1 내지 10, 생강 1 내지 10 및 대추 1 내지 10의 중량부(w/w)임을 특징으로 하는 약학 조성물.The method according to claim 1,
The combination weight of the combination herbal medicine extract is 1 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10, wax 1 to 10, manganese 1 to 10, and manganese 1 to 10 parts by weight (w / w); (b) In the case of a combination of red pepper, red pepper, red pepper, yongcheng, mulberry, mulberry, astringent gong, ginger and jujube, (W / w) of 10 to 10, 2 to 10, 1 to 10, ginger 1 to 10 and 1 to 10 of jujubes.
상기 조합생약 추출물은 정제수를 포함한 물, C1 내지 C4의 저급알코올 또는 이들의 혼합용매에 가용한 추출물임을 특징으로 하는 약학조성물. The method according to claim 1,
Wherein the combined herbal medicine extract is an extract which is soluble in water containing purified water, lower alcohol of C1 to C4 or a mixed solvent thereof.
상기 조합생약 추출물의 배합 중량부는 (a) 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동의 조합인 경우는, 백출 1 내지 10, 상심자 1 내지 10, 구기자 1 내지 10, 용안육 1 내지 10, 우슬 1 내지 10, 두충 1 내지 10, 및 천문동 1 내지 10의 중량부(w/w)이며; (b) 백출, 상심자, 구기자, 용안육, 우슬, 두충, 천문동, 생강 및 대추의 조합인 경우는, 백출 1 내지 10, 상심자 1 내지 10, 구기자 1 내지 10, 용안육 1 내지 10, 우슬 1 내지 10, 두충 1 내지 10, 천문동 1 내지 10, 생강 1 내지 10 및 대추 1 내지 10의 중량부(w/w)임을 특징으로 하는 건강기능식품.The method according to claim 6,
The combination weight of the combination herbal medicine extract is 1 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10, wax 1 to 10, manganese 1 to 10, and manganese 1 to 10 parts by weight (w / w); (b) In the case of a combination of red pepper, red pepper, red pepper, yongcheng, mulberry, mulberry, astringent gong, ginger and jujube, (W / w) of 10 to 10, 2 to 10, 1 to 10, ginger 1 to 10 and 1 to 10 of jujubes.
상기 조합생약 추출물의 배합 중량부는 (a) 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동의 조합인 경우는, 백출 1 내지 10, 상심자 1 내지 10, 구기자 1 내지 10, 용안육 1 내지 10, 우슬 1 내지 10, 두충 1 내지 10, 및 천문동 1 내지 10의 중량부(w/w)이며; (b) 백출, 상심자, 구기자, 용안육, 우슬, 두충, 천문동, 생강 및 대추의 조합인 경우는, 백출 1 내지 10, 상심자 1 내지 10, 구기자 1 내지 10, 용안육 1 내지 10, 우슬 1 내지 10, 두충 1 내지 10, 천문동 1 내지 10, 생강 1 내지 10 및 대추 1 내지 10의 중량부(w/w)임을 특징으로 하는 건강보조식품.10. The method of claim 9,
The combination weight of the combination herbal medicine extract is 1 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10, wax 1 to 10, manganese 1 to 10, and manganese 1 to 10 parts by weight (w / w); (b) In the case of a combination of red pepper, red pepper, red pepper, yongcheng, mulberry, mulberry, astringent gong, ginger and jujube, (W / w) of 1 to 10, 2 to 10, 1 to 10, ginger 1 to 10 and 1 to 10 of jujubes.
상기 조합생약 추출물의 배합 중량부는 (a) 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동의 조합인 경우는, 백출 1 내지 10, 상심자 1 내지 10, 구기자 1 내지 10, 용안육 1 내지 10, 우슬 1 내지 10, 두충 1 내지 10, 및 천문동 1 내지 10의 중량부(w/w)이며; (b) 백출, 상심자, 구기자, 용안육, 우슬, 두충, 천문동, 생강 및 대추의 조합인 경우는, 백출 1 내지 10, 상심자 1 내지 10, 구기자 1 내지 10, 용안육 1 내지 10, 우슬 1 내지 10, 두충 1 내지 10, 천문동 1 내지 10, 생강 1 내지 10 및 대추 1 내지 10의 중량부(w/w)임을 특징으로 하는 갱년기 영양보충제.13. The method of claim 12,
The combination weight of the combination herbal medicine extract is 1 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10 to 10, 10, wax 1 to 10, manganese 1 to 10, and manganese 1 to 10 parts by weight (w / w); (b) In the case of a combination of red pepper, red pepper, red pepper, yongcheng, mulberry, mulberry, astringent gong, ginger and jujube, (W / w) of 1 to 10, 2 to 10, 1 to 10, ginger 1 to 10 and 1 to 10 of jujube.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170036775A KR101793531B1 (en) | 2017-03-23 | 2017-03-23 | A composition and functional food comprising an combination extract of Atractylodes macrocephala KOIDZ, Morus alba L., Lycium chinensis, Euphoria lingan STEUD, Achyranthus japonica NAKAI, Eucommia ulmoides OLIV and Asparagus cochinchinensis MERR for preventing or treating postmenopause syndrome |
PCT/KR2018/002803 WO2018174448A1 (en) | 2017-03-23 | 2018-03-09 | Composition for treating and preventing climacteric syndrome containing combined herbal medicinal extract of white atractylis, mori fructus, chinese matrimony vine, longan, achyranthes, eucommia bark, and asparagus cochinchinensis merr. as active ingredient, and use of same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170036775A KR101793531B1 (en) | 2017-03-23 | 2017-03-23 | A composition and functional food comprising an combination extract of Atractylodes macrocephala KOIDZ, Morus alba L., Lycium chinensis, Euphoria lingan STEUD, Achyranthus japonica NAKAI, Eucommia ulmoides OLIV and Asparagus cochinchinensis MERR for preventing or treating postmenopause syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101793531B1 true KR101793531B1 (en) | 2017-11-03 |
Family
ID=60383974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170036775A KR101793531B1 (en) | 2017-03-23 | 2017-03-23 | A composition and functional food comprising an combination extract of Atractylodes macrocephala KOIDZ, Morus alba L., Lycium chinensis, Euphoria lingan STEUD, Achyranthus japonica NAKAI, Eucommia ulmoides OLIV and Asparagus cochinchinensis MERR for preventing or treating postmenopause syndrome |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101793531B1 (en) |
WO (1) | WO2018174448A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018174448A1 (en) * | 2017-03-23 | 2018-09-27 | 김순일 | Composition for treating and preventing climacteric syndrome containing combined herbal medicinal extract of white atractylis, mori fructus, chinese matrimony vine, longan, achyranthes, eucommia bark, and asparagus cochinchinensis merr. as active ingredient, and use of same |
CN109846963A (en) * | 2019-04-03 | 2019-06-07 | 江西安顺堂生物科技有限公司 | A kind of health care product tonify the kidney to relieve mental strain, fill blood, alleviating neural anxiety, improving sleep |
WO2020085633A1 (en) * | 2018-10-24 | 2020-04-30 | 에스케이바이오랜드 주식회사 | Cosmetic composition comprising hardy rubber tree bark extract for cooling skin or reducing skin redness |
CN111700950A (en) * | 2020-07-20 | 2020-09-25 | 花姐生物科技(杭州)有限公司 | Natural-source anti-anxiety sleep-aiding sublingual tablet |
KR20200140071A (en) * | 2019-06-05 | 2020-12-15 | 아주대학교산학협력단 | Composition for preventing or treating osteoporosis comprising complex extract of lycii radicis cortex and achyranthes japonica nakai, and analysis method for standardization thereof |
KR20220049672A (en) * | 2020-10-14 | 2022-04-22 | 주식회사 필홀딩스 | Composition including oriental medicine for improvement of muscular pain and process of treating thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115530368A (en) * | 2022-07-08 | 2022-12-30 | 山东康美药业有限公司 | Preparation method of soft extract for tonifying qi and blood, resisting oxidation and delaying aging |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000103718A (en) * | 1998-09-28 | 2000-04-11 | Pola Chem Ind Inc | Composition for improving activity of living body |
KR100419121B1 (en) * | 2002-07-15 | 2004-02-18 | 주식회사 한국인삼공사 | A functional food Containing herbes composition for female menopausal disorder |
KR20130039309A (en) * | 2011-10-11 | 2013-04-19 | 김선미 | Garlic and yolk extract including functionality food composite for health |
KR101451755B1 (en) * | 2013-08-05 | 2014-10-16 | 동우당제약(주) | A composition for preventing bone metabolism-related diseases and increasing bone function comprising mix extracts of Mori Fructus and Aralia Continentalis |
KR101793531B1 (en) * | 2017-03-23 | 2017-11-03 | 김순일 | A composition and functional food comprising an combination extract of Atractylodes macrocephala KOIDZ, Morus alba L., Lycium chinensis, Euphoria lingan STEUD, Achyranthus japonica NAKAI, Eucommia ulmoides OLIV and Asparagus cochinchinensis MERR for preventing or treating postmenopause syndrome |
-
2017
- 2017-03-23 KR KR1020170036775A patent/KR101793531B1/en active IP Right Grant
-
2018
- 2018-03-09 WO PCT/KR2018/002803 patent/WO2018174448A1/en active Application Filing
Non-Patent Citations (1)
Title |
---|
대한한방부인과학회지. 2008. Vol.21, No.3, pp.257-268. |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018174448A1 (en) * | 2017-03-23 | 2018-09-27 | 김순일 | Composition for treating and preventing climacteric syndrome containing combined herbal medicinal extract of white atractylis, mori fructus, chinese matrimony vine, longan, achyranthes, eucommia bark, and asparagus cochinchinensis merr. as active ingredient, and use of same |
WO2020085633A1 (en) * | 2018-10-24 | 2020-04-30 | 에스케이바이오랜드 주식회사 | Cosmetic composition comprising hardy rubber tree bark extract for cooling skin or reducing skin redness |
CN109846963A (en) * | 2019-04-03 | 2019-06-07 | 江西安顺堂生物科技有限公司 | A kind of health care product tonify the kidney to relieve mental strain, fill blood, alleviating neural anxiety, improving sleep |
KR20200140071A (en) * | 2019-06-05 | 2020-12-15 | 아주대학교산학협력단 | Composition for preventing or treating osteoporosis comprising complex extract of lycii radicis cortex and achyranthes japonica nakai, and analysis method for standardization thereof |
KR102320679B1 (en) | 2019-06-05 | 2021-11-02 | 아주대학교산학협력단 | Composition for preventing or treating osteoporosis comprising complex extract of lycii radicis cortex and achyranthes japonica nakai, and analysis method for standardization thereof |
CN111700950A (en) * | 2020-07-20 | 2020-09-25 | 花姐生物科技(杭州)有限公司 | Natural-source anti-anxiety sleep-aiding sublingual tablet |
KR20220049672A (en) * | 2020-10-14 | 2022-04-22 | 주식회사 필홀딩스 | Composition including oriental medicine for improvement of muscular pain and process of treating thereof |
KR102425282B1 (en) | 2020-10-14 | 2022-07-28 | 주식회사 필홀딩스 | Composition including oriental medicine for improvement of muscular pain and process of treating thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2018174448A1 (en) | 2018-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101793531B1 (en) | A composition and functional food comprising an combination extract of Atractylodes macrocephala KOIDZ, Morus alba L., Lycium chinensis, Euphoria lingan STEUD, Achyranthus japonica NAKAI, Eucommia ulmoides OLIV and Asparagus cochinchinensis MERR for preventing or treating postmenopause syndrome | |
Kulkarni et al. | Indian gooseberry (Emblica officinalis): Complete pharmacognosy review | |
KR100980819B1 (en) | The composition comprising complex herbal extract as an active ingredient and the preparation method thereof | |
KR20130003520A (en) | Composition for preventing or relieving alcohol-induced hangover comprising medicinal herbs | |
KR100771524B1 (en) | Composition for improving liver function comprising herbal mixture extract | |
KR20070101443A (en) | Composition for removing hangover comprising herbal mixture extract | |
KR100874187B1 (en) | Composition comprising complex herbal extracts having the effect of preventing and treating stroke and degenerative neurological diseases | |
KR20160000695A (en) | Herbal-medicine containing dha for recovering fatigue and enhancing memory, and method of manufacturing the same | |
KR100522579B1 (en) | Pharmaceutical composition comprising the extracts of scutellaria root and schizandra fruit mixture thereof having an effect of restraint stress | |
KR102416513B1 (en) | Composition for preventing and improving pet constipation and manufacturing method thereof | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
KR100673266B1 (en) | A growth-promoting composition | |
KR100585562B1 (en) | Crude drug composition for treating or alleviating inflammatory disease | |
KR100592488B1 (en) | Composition comprising the extract of crude drug complex having neuronal cell-protecting activity for preventing and treating the degenerative brain disease | |
KR101783549B1 (en) | Health supplement food containing dha for recovering fatigue, and method of manufacturing the same | |
KR101016837B1 (en) | Composition comprising the extract of Lonicera japonica THUNB. preventing and treating arthritis | |
KR100850503B1 (en) | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex | |
KR100679290B1 (en) | A composition comprising an extract of ?????201 crude drug complex as an effective ingredient treating or preventing obesity | |
KR20190001112A (en) | Anti-obesity composition comprising Protaetia brevitarsis seulensis larva extracts | |
KR101479096B1 (en) | Health functional food comprising extracts of herbal mixture for preventing or improving edema of delivered or pregnant woman | |
KR100638344B1 (en) | Composition comprising the crude drug extract for improving eye symptoms of VDT syndrome | |
KR101801130B1 (en) | A Composition Comprising the combined herbal extract for preventing or improving the hormonal abnormal syndrome in women | |
JP6063499B2 (en) | Pharmaceutical composition for prevention and treatment of male infertility containing dough yellow, eggplant, agarwood, persimmon, a mixture of ginseng and honey as active ingredients | |
KR102651713B1 (en) | Chocolate composition for relieving hangovers comprising Hovenia Dulcis fruit and Velvet Antlers, and the manufacturing method of chocolate for relieving hangovers using the same | |
KR100881368B1 (en) | Composition comprising mixed herbal extract for preventing and treating depression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |